Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
173.04
-0.88 (-0.51%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
July 26, 2024
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards...
Via
Benzinga
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
July 26, 2024
Biogen partner Eisai is planning to ask European regulators to re-examine their decision.
Via
Investor's Business Daily
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
July 26, 2024
From
Biogen Inc.
Via
GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Key Takeaways From Biogen Analyst Ratings
July 12, 2024
Via
Benzinga
Will BIOGEN INC breakout?
July 11, 2024
Technical Insights for BIOGEN INC (NASDAQ:BIIB): Is a Breakout Imminent?
Via
Chartmill
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
July 29, 2024
Biogen stock has slipped 18% so far this year.
Via
The Motley Fool
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 26, 2024
Via
Benzinga
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
July 24, 2024
Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps.
Via
Benzinga
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
July 24, 2024
The companies are no longer developing their drug for essential tremor treatment.
Via
Investor's Business Daily
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
July 24, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Biogen previously decided against opting into Ionis' Angelman program.
Via
Investor's Business Daily
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 22, 2024
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
July 19, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 19, 2024
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
July 18, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
July 16, 2024
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Via
Investor's Business Daily
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 16, 2024
From
Schall Law
Via
GlobeNewswire
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
July 15, 2024
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER ALERT: Only 7 Days Remain For Investors To Move For Lead Plaintiff in Biogen Inc.
July 15, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
July 15, 2024
Revenue is climbing at these two drug companies -- and the trend should continue.
Via
The Motley Fool
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
July 13, 2024
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.
Via
The Motley Fool
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
July 12, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm
July 11, 2024
From
Kirby McInerney LLP
Via
GlobeNewswire
BIIB Investors Have Opportunity to Join Biogen Inc. Securities Fraud Investigation with the Schall Law Firm
July 11, 2024
From
The Schall Law Firm
Via
Business Wire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 09, 2024
From
Schall Law
Via
GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
July 08, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.